Literature DB >> 3105167

Immunohistological characterization of a monoclonal antibody (OV632) against epithelial ovarian carcinomas.

G J Fleuren, E G Coerkamp, M Nap, L J vd Broek, S O Warnaar.   

Abstract

A hybridoma cell line (OV632) producing monoclonal antibody against ovarian carcinomas was developed from the spleen cells of a mouse immunized with cystic fluid from a serous cystadenocarcinoma. Immunohistological studies in frozen sections showed that 22 out of 28 nonmucinous ovarian carcinomas, which included serous, endometrioid, clear cell, and undifferentiated tumours, reacted with this antibody. Three out of 7 mucinous ovarian carcinomas were positive, whereas only 7 out of 122 extra-genital malignant lesions, predominantly adenocarcinomas, were positive. The negative cases included 38 breast carcinomas and 24 colon carcinomas, tumours which are responsible for most of metastatic disease in the ovary. On the basis of these findings, the antibody OV632 is considered appropriate for histodiagnostic purposes as an aid in the distinction between primary and secondary ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105167     DOI: 10.1007/bf00781682

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  19 in total

1.  Clinical aspects of metastatic ovarian cancer of extragenital origin.

Authors:  H JOHANSSON
Journal:  Acta Obstet Gynecol Scand       Date:  1960       Impact factor: 3.636

2.  The tumor marker CA 125 is a common constituent of normal cervical mucus.

Authors:  H W de Bruijn; T van Beeck Calkoen-Carpay; S Jager; J M Duk; J G Aalders; G J Fleuren
Journal:  Am J Obstet Gynecol       Date:  1986-05       Impact factor: 8.661

3.  The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).

Authors:  S E Vogl; M Berenzweig; B H Kaplan; M Moukhtar; W Bulkin
Journal:  Cancer Treat Rep       Date:  1979-02

Review 4.  Biochemical markers in the plasma and tumors of patients with gynecologic malignancies.

Authors:  J R van Nagell; E S Donaldson; M B Hanson; E C Gay; E J Pavlik
Journal:  Cancer       Date:  1981-07-15       Impact factor: 6.860

5.  Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Authors:  M J Mattes; C Cordon-Cardo; J L Lewis; L J Old; K O Lloyd
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

6.  Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125.

Authors:  S E Kabawat; R C Bast; A K Bhan; W R Welch; R C Knapp; R B Colvin
Journal:  Int J Gynecol Pathol       Date:  1983       Impact factor: 2.762

7.  The value of tumour marker CA 125 in surgical pathology.

Authors:  I A Koelma; M Nap; C J Rodenburg; G J Fleuren
Journal:  Histopathology       Date:  1987-03       Impact factor: 5.087

8.  Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types.

Authors:  S E Kabawat; R C Bast; W R Welch; R C Knapp; R B Colvin
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

9.  Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma.

Authors:  E Oosterwijk; D J Ruiter; J C Wakka; J W Huiskens-van der Meij; U Jonas; G J Fleuren; J Zwartendijk; P Hoedemaeker; S O Warnaar
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

10.  Immunoperoxidase localization of a high-molecular-weight mucin recognized by monoclonal antibody 1D3.

Authors:  A Gangopadhyay; M Bhattacharya; S K Chatterjee; J J Barlow; Y Tsukada
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

View more
  4 in total

1.  Imaging of ovarian cancer with radiolabelled monoclonal antibodies.

Authors:  D L van Kranenburg; M J van Kroonenburgh; J B Trimbos; G J Fleuren; E K Pauwels
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

2.  Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody.

Authors:  C Y Lee; K W Chen; F S Sheu; A Tsang; K C Chao; H T Ng
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Changes in expression of differentiation markers between normal ovarian cells and derived tumors.

Authors:  C C Van Niekerk; F C Ramaekers; A G Hanselaar; J Aldeweireldt; L G Poels
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

4.  OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.

Authors:  C Edwards; J Oates
Journal:  J Clin Pathol       Date:  1995-07       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.